These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33979259)

  • 1. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.
    Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
    Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
    Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines.
    Marampon F; Di Nisio V; Pietrantoni I; Petragnano F; Fasciani I; Scicchitano BM; Ciccarelli C; Gravina GL; Festuccia C; Del Fattore A; Tombolini M; De Felice F; Musio D; Cecconi S; Tini P; Maddalo M; Codenotti S; Fanzani A; Polimeni A; Maggio R; Tombolini V
    Cancer Lett; 2019 Oct; 461():90-101. PubMed ID: 31325529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
    Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
    J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.
    Marampon F; Codenotti S; Megiorni F; Del Fattore A; Camero S; Gravina GL; Festuccia C; Musio D; De Felice F; Nardone V; Santoro AN; Dominici C; Fanzani A; Pirtoli L; Fioravanti A; Tombolini V; Cheleschi S; Tini P
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):881-893. PubMed ID: 30701326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
    Camero S; Ceccarelli S; De Felice F; Marampon F; Mannarino O; Camicia L; Vescarelli E; Pontecorvi P; Pizer B; Shukla R; Schiavetti A; Mollace MG; Pizzuti A; Tombolini V; Marchese C; Megiorni F; Dominici C
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):137-152. PubMed ID: 30357520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma.
    Camero S; Milazzo L; Vulcano F; Ceccarelli F; Pontecorvi P; Pedini F; Rossetti A; Scialis ES; Gerini G; Cece F; Pomella S; Cassandri M; Porrazzo A; Romano E; Festuccia C; Gravina GL; Ceccarelli S; Rota R; Lotti LV; Midulla F; Angeloni A; Marchese C; Marampon F; Megiorni F
    BMC Cancer; 2024 Jul; 24(1):814. PubMed ID: 38977944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization.
    Petragnano F; Pietrantoni I; Camero S; Codenotti S; Milazzo L; Vulcano F; Macioce G; Giordani I; Tini P; Cheleschi S; Gravina GL; Festuccia C; Rossetti A; Delle Monache S; Ordinelli A; Ciccarelli C; Mauro A; Barbara B; Antinozzi C; Schiavetti A; Maggio R; Di Luigi L; Polimeni A; Marchese C; Tombolini V; Fanzani A; Bernabò N; Megiorni F; Marampon F
    J Biomed Sci; 2020 Aug; 27(1):90. PubMed ID: 32854690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FK228 sensitizes radioresistant small cell lung cancer cells to radiation.
    Li H; Ma L; Bian X; Lv Y; Lin W
    Clin Epigenetics; 2021 Feb; 13(1):41. PubMed ID: 33632300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
    Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
    Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
    Marampon F; Gravina GL; Di Rocco A; Bonfili P; Di Staso M; Fardella C; Polidoro L; Ciccarelli C; Festuccia C; Popov VM; Pestell RG; Tombolini V; Zani BM
    Mol Cancer Ther; 2011 Jan; 10(1):159-68. PubMed ID: 21220498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.
    Bergantin E; Quarta C; Nanni C; Fanti S; Pession A; Cantelli-Forti G; Tonelli R; Hrelia P
    Cancer Biol Ther; 2014 Sep; 15(9):1219-25. PubMed ID: 24971463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
    Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
    Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo.
    Asperti M; Cantamessa L; Gryzik M; Bugatti M; Codenotti S; Denardo A; Vermi W; Fanzani A; Poli M
    Clin Exp Med; 2023 Oct; 23(6):2487-2502. PubMed ID: 36764998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
    Allen-Rhoades W; Lupo PJ; Scheurer ME; Chi YY; Kuttesch JF; Venkatramani R; Meyer WH; Mascarenhas L
    Cancer Med; 2023 May; 12(9):10222-10229. PubMed ID: 37016270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo.
    Paillas S; Then CK; Kilgas S; Ruan JL; Thompson J; Elliott A; Smart S; Kiltie AE
    Int J Radiat Oncol Biol Phys; 2020 May; 107(1):212-221. PubMed ID: 31987970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.